Key result
IL-22 drives atherosclerosis via JAK/STAT signaling, promoting vascular remodeling, inflammation, and lipid dysregulation.
Answers are grounded in this paper and cite their sources.
Review demonstrates how interleukin-22 signaling drives vascular inflammation and arterial plaque formation, highlighting its promise as an anti-atherosclerotic therapeutic target.
BACKGROUND: Atherosclerosis is recognized as a chronic immuno-inflammatory disease that is characterized by the accumulation of immune cells and lipids in the vascular wall. In this review, we focus on the latest advance regarding the regulation and signaling pathways of IL-22 and highlight its impacts on atherosclerosis. MAIN BODY: IL-22, an important member of the IL-10 family of cytokines, is released by cells of the adaptive and innate immune system and plays a key role in the development of inflammatory diseases. The binding of IL-22 to its receptor complex can trigger a diverse array of downstream signaling pathways, in particular the JAK/STAT, to induce the expression of chemokines and proinflammatory cytokines. Recently, numerous studies suggest that IL-22 is involved in the pathogenesis of atherosclerosis by regulation of VSMC proliferation and migration, angiogenesis, inflammatory response, hypertension, and cholesterol metabolism. CONCLUSION: IL-22 promotes the development of atherosclerosis by multiple mechanisms, which may be a promising therapeutic target in the pathogenesis of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2021) conducted a review in Atherosclerosis. Interleukin-22 (IL-22) was evaluated. Interleukin-22 (IL-22) promotes atherosclerosis via JAK/STAT signaling, regulating VSMC proliferation, angiogenesis, inflammation, hypertension, and cholesterol metabolism.
Synapse has enriched 10 related papers. Consider them for comparative context: